122320-76-7

Upstream product

• 615-18-9 2-chloro-1,3-benzoxazole 
• 109-83-1 (2-hydroxyethyl)(methyl)amine 
• 123-08-0 4-hydroxy-benzaldehyde 
• 122320-77-8 2-[N-methyl-N-(2-benzoxazolyl)-amino]ethanol 
• 1972-28-7 diethylazodicarboxylate 
• 122320-97-2 methanesulfonic acid 2-(benzooxazol-2-ylmethylamino)ethyl ester 

Downstream Products

• 236393-21-8 ethyl (E/Z)-3-<4-<2-ethoxy>phenyl>-2-(3-trifluoromethylphenoxy)propenoate 
• 236110-85-3 <3(2S,3R),4S>-3-<3-<4-<2-ethoxy>phenyl>-2-ethoxy-3-hydroxypropanoyl>-4-benzyloxazolidin-2-one 
• 177785-29-4 <3(2S,3R),4S>-3-<3-<4-<2-ethoxy>phenyl>-3-hydroxy-2-(2-methoxyethoxy)propanoyl>-4-benzyloxazolidin-2-one 

Relevant academic research and scientific papers

Design and synthesis of benzoxazole containing indole analogs as peroxisome proliferator-activated receptor-γ/δ dual agonists

A series of benzoxazole or benzothiazole containing indole analogs, 6-alkoxyindole-2-carboxylic acids and 5-alkoxy-3-indolylacetic acids, were synthesized as novel candidates of PPARγ/δ dual agonists and their ligand activities for PPAR subtypes (α, γ, an

HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR INHIBITING LIPID ACCUMULATION CONTAINING SAME

The present invention relates to a novel heterocyclic carboxylic acid derivative, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for inhibiting the accumulation of lipids in the body.

Antihyperglycemic activity of new 1,2,4-oxadiazolidine-3,5-diones

A series of 1,2,4-oxadiazolidine-3,5-diones was synthesized and evaluated as oral antihyperglycemic agents in the obese insulin resistant db/db and ob/ob mouse - the two models for Type 2 diabetes mellitus. The majority of the prepared methoxy- and ethoxy-linked oxazole 1,2,4-oxadiazolidine-3,5-diones normalized plasma glucose levels at the 100 mg kg-1 oral dose in the db/db diabetic mouse model, and several amongst them reduced the glucose levels at the 20 mg kg-1 oral dose. The most potent compounds in the db/db mouse model were also active in the ob/ob mouse model normalizing the plasma glucose levels at the 20 mg kg-1 oral dose. The trifluoromethoxy analog 32 was the most active compound of the series, reducing significantly the plasma glucose levels at the 5 mg kg-1 oral dose. Oxadiazole-tailed 1,2,4-oxadiazolidine-3,5-diones were also active in both the db/db and ob/ob diabetic mouse models normalizing plasma glucose levels at the 100 mg kg-1 oral dose.

benzyl>-2,4-thiazolidinediones as Potent Antihyperglycemic Agents

A series of -2,4-thiazolidinediones and benzyl>-2,4-thiazolidinediones was synthesized from the corresponding aldehydes.Compounds from the urea series, exemplified by 16, showed antihyperglycemic potency comparable with known agents of the type such as pioglitazone and troglitazone (CS-045).The benzoxazole 49, a cyclic analogue of 16, was a very potent enhancer of insulin sensitivity, and by modification of the aromatic heterocycle, an aminopyridine, 37, was identified as a lead compound from SAR studies.Evaluation of antihyperglycemic activity together with effects on blood hemoglobin content, to determine the therapeutic index, was performed in 8-day repeat administration studies in genetically obese C57 BI/6 ob/ob mice.From these studies, BRL 49653 (37) has been selected, on the basis of antihyperglycemic potency combined with enhanced selectivity against reductions in blood hemoglobin content, for further evaluation.